ImmunityBio Inc. Stock
€6.52
Your prediction
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | -9.970% | 31.757% | 52.089% | 125.529% | 314.772% | 151.528% | -76.265% |
| Biocryst Pharmaceuticals | 0.970% | 6.900% | 7.459% | -31.214% | -5.949% | -35.251% | -30.843% |
| Heron Therapeutics Inc. | 0.970% | 1.061% | -21.875% | -39.099% | -10.233% | -59.283% | -93.364% |
| Madrigal Pharmaceuticals inc. | -10.090% | 3.064% | -3.583% | 28.338% | -16.329% | 46.866% | 312.766% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission
Why ImmunityBio Stock Is Soaring Today
Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label